Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Currently submitted to: JMIR mHealth and uHealth

Date Submitted: Oct 26, 2025
Open Peer Review Period: Nov 17, 2025 - Jan 12, 2026
(closed for review but you can still tweet)

NOTE: This is an unreviewed Preprint

Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).

Peer review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.

Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).

Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.

Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.

Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Effectiveness, usability and acceptability of a mobile app focus on blood pressure control in adults with hypertension (Pressão na Boa): a randomized controlled trial

  • Eduardo Johann; 
  • Marcelo Baggio do Amaral; 
  • Antonio Cleilson Nobre Bandeira; 
  • Maria Eduarda Sirydakis; 
  • Juliana Pinto da Silveira; 
  • Allana Andrade Souza; 
  • João Batista de Oliviera Junior; 
  • Carla Elane Silva dos Santos; 
  • Rodrigo Sudatti Delevatti; 
  • Cassiano Ricardo Rech; 
  • Breno Quintella Farah; 
  • Gabriel Grizzo Cucato; 
  • Raphael Mendes Ritti-Dias; 
  • Aline Gerage

ABSTRACT

Background:

Systemic arterial hypertension is an important risk factor for cardiovascular diseases and a major public health problem. Despite available treatments, low adherence to treatment and insufficient levels of disease control are still observed. Therefore, innovative methodologies to improve this scenario are needed. Mobile health interventions (apps) are emerging as an alternative, showing improvements in various parameters related to the treatment of hypertension. However, most of these interventions are conducted in high-income countries.

Objective:

This study aimed to evaluate the effects and the usability and acceptability of a mobile application-based intervention (Pressão na Boa) on blood pressure (BP), medication adherence, and lifestyle in hypertensive adults.

Methods:

This trial was conducted with hypertensive adults, randomly allocated into two groups: control group (CG) and App group (AG). The AG was submitted to an intervention based on a mobile app (Pressão na Boa) during eight weeks. Laboratory BP, medication adherence, lifestyle, accelerometry, usability and acceptability of the App were assessed at pre- and post-intervention.

Results:

Fifty-two individuals participated in the study (AG: n = 26 and CG: n = 26). A significant main effect of time was observed on BP with reductions from pre- to post-intervention in both groups (p<0.001). A significant group-by-time interaction was found for sedentary behavior (p = 0.004) and light PA (p = 0.012), with the CG showing great effect sizes. The app received positive evaluations regarding the system usability. Most participants emphasized the functionality in supporting BP control but some barriers to its use, such as small icons and fonts, the lack of memory to record diary physical activities, and the lack of familiarity and comfort with the technology.

Conclusions:

The intervention using the mobile app Pressão na Boa led to a decrease in BP for hypertensive patients, showing a slightly larger effect compared to a counseling lecture on hypertension treatment. While the app was evaluated positively overall, it needs enhancements to improve its support for managing hypertension. Clinical Trial: Registry name: Effectiveness and Usability of a Mobile Application to Assist in the Treatment of Arterial Hypertension. URL: https://clinicaltrials.gov/study/NCT05575232 Registration number: NCT05575232.


 Citation

Please cite as:

Johann E, do Amaral MB, Bandeira ACN, Sirydakis ME, da Silveira JP, Souza AA, de Oliviera Junior JB, dos Santos CES, Delevatti RS, Rech CR, Farah BQ, Cucato GG, Ritti-Dias RM, Gerage A

Effectiveness, usability and acceptability of a mobile app focus on blood pressure control in adults with hypertension (Pressão na Boa): a randomized controlled trial

JMIR Preprints. 26/10/2025:86552

DOI: 10.2196/preprints.86552

URL: https://preprints.jmir.org/preprint/86552

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.